Related references
Note: Only part of the references are listed.SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the don't eat me signal and activating the eat me signal
Jifeng Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response
Elizabeth R. Stirling et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Loss of CD47 alters CD8+T cell activation in vitro and immunodynamics in mice
Pulak R. Nath et al.
ONCOIMMUNOLOGY (2022)
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma
Zhicheng Zhou et al.
CANCER CELL (2022)
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Zhenhua Ren et al.
JOURNAL OF CLINICAL INVESTIGATION (2022)
Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial
Jianming Xu et al.
ONCOIMMUNOLOGY (2021)
First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.
Aflah Roohullah et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors
Anli Zhang et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Anti-CD47 Monoclonal Antibody-Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
Yingnan Si et al.
VACCINES (2021)
Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
Rujiao Liu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
Jibin Zhang et al.
MABS (2020)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Combination of CD47 and signal-regulatory protein-α constituting the don't eat me signal is a prognostic factor in diffuse large B-cell lymphoma
Ryo Kazama et al.
CANCER SCIENCE (2020)
Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy
Jie Liu et al.
JCI INSIGHT (2020)
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
Yan Song et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The design, analysis and application of mouse clinical trials in oncology drug development
Sheng Guo et al.
BMC CANCER (2019)
High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis
Jingping Yuan et al.
ONCOLOGY LETTERS (2019)
Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients
Jingping Yuan et al.
CANCER CELL INTERNATIONAL (2019)
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
Jie Wang et al.
MABS (2019)
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation
Anthony L. Schwartz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia
Kun Yang et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma
Thomas Valerius et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses
Boning Liu et al.
MABS (2018)
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
Xuexiang Du et al.
CELL RESEARCH (2018)
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience
Alecia S. Folkes et al.
CURRENT OPINION IN ONCOLOGY (2018)
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Vanessa Buatois et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Xiaojuan Liu et al.
CELL REPORTS (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Xiaoyu An et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2018)
Is CD47 an innate immune checkpoint for tumor evasion?
Xiaojuan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies
Lan Wang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
Targeting CD47 Enhances the Efficacy of Anti-PD-1 and CTLA-4 in an Esophageal Squamous Cell Cancer Preclinical Model
Hua Tao et al.
ONCOLOGY RESEARCH (2017)
Experimental animal modeling for immuno-oncology
Qi-Xiang Li et al.
PHARMACOLOGY & THERAPEUTICS (2017)
TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets
Gloria H. Y. Lin et al.
PLOS ONE (2017)
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Reid W. Merryman et al.
BLOOD ADVANCES (2017)
Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines
Sheng Guo et al.
CANCER RESEARCH (2016)
SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
Emily C. Piccione et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Targeting immune checkpoints in lymphoma
Stephen M. Ansell
CURRENT OPINION IN HEMATOLOGY (2015)
A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells
Emily C. Piccione et al.
MABS (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Hui Gao et al.
NATURE MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations
Dawei Chen et al.
ONCOTARGET (2015)
CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy
David R. Soto-Pantoja et al.
CANCER RESEARCH (2014)
The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment
Chika Iwamoto et al.
EXPERIMENTAL HEMATOLOGY (2014)
Polymorphic Sirpa is the genetic determinant for NOD-based mouse lines to achieve efficient human cell engraftment
Takuji Yamauchi et al.
BLOOD (2013)
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients
Mengmeng Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
D. Kim et al.
LEUKEMIA (2012)
Patient-derived tumour xenografts as models for oncology drug development
John J. Tentler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen B. Willingham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Mark P. Chao et al.
CANCER RESEARCH (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies
KD Lute et al.
BLOOD (2005)
Share Paper
